What’s heart failure C linical syndrome identified by presence of current or prior characteristic symptoms; List them Heart cannot pump blood commensurate to needs Usually elevated filling pressures to compensate for needs
Classification HF with LVEF ≤40 percent (HFrEF). HF with LVEF of 41 to 49 percent (HFmrEF). HF with LVEF ≥50 percent (HFpEF) Functional Status is usually with NYHA I - IV
Clinical Presentation History is the key Fluid overload: PND, orthopnoea, abdominal distension, bilateral lower limb swelling, Difficulty in breathing (pul.edema) Reduced cardiac output: Fatigue, exertional dyspnoea Any other presentation from the cause of decompensation: Infections,anemia etc
Examination findings Vary from case to case Always remember IPPA model CVS: Resp : Abdominal : General Exam :
Diagnosis Mainly Clinical plus a Echocardiogram Modified Framingham Criteria: Less favoured but still used Lab Tests: Based on history CBC: Anemia , sepsis UECs : Electrolytes, AKI or CKD LFTs: High GGT 2* UL Lipid profile: ASCVD score: Need for statins NT proBNP Troponins T or I
Approach To treatment Goals: Reduce mortality, Improve quality of life,reduce symptoms, Reduce hospital stay. Manage underlying condition: Cardiomyopathies, Arrhythmias Optimal BP Control: BP 140/90 Fluid restriction to 1.5 L/24 hrs .Input output monitoring Manage Concomitant conditions :DM, COPD Follow up plan devised: Volume status, compliance, BP control plus ... Patient Counselling
Approach To treatment Goals: Reduce mortality, Improve quality of life,reduce symptoms, Reduce hospital stay. Manage underlying condition: Cardiomyopathies, Arrhythmias Optimal BP Control: BP 140/90 Fluid restriction to 1.5 L/24 hrs .Input output monitoring Manage Concomitant conditions :DM, COPD Follow up plan devised: Volume status, compliance, BP control plus ... Patient Counselling
Pharmacologic treatment Diuresis in fluid overload The 4 major classes of drugs: Have mortality benefit and patient must be on them Clinical management of ascites BB in COPD Renal dosing of drugs if associated Kidney impairment Why SGLT 2: Mortality benefit: DAPA HF trial, EMPEROR trial